[13] [11] Other GLP-1 receptor agonists have demonstrated renoprotective effects in dedicated outcome trials, though these findings cannot be automatically extrapolated to tirzepatide
Initial targets included compounding pharmacies like Strive and Empower, which Lilly accused of continuing to produce mass-manufactured tirzepatide while falsely marketing it as "personalized" medication
The FDA has issued specific warnings about compounded GLP-1 medications, including concerns about quality control and manufacturing practices
Tirzepatide, a dual GLP-1 / glucose-dependent insulinotropic polypeptide (GIP) agonist, was superior to semaglutide in reducing HbA 1c and body weight in the SURPASS-2 trial, a phase 3, randomised, open-label trial comparing the efficacy and safety of tirzepatide vs semaglutide once weekly as add-on therapy to metformin in individuals with type 2 diabetes [10]
Each of these has limited but suggestive data
New research underway More trials are now starting to look at how GLP-1s might influence things like chronic inflammation or immunosuppression, both of which might contribute to cancer growth